RLYB · Rallybio Corporation

0001628280-26-022385

Summary

Rallybio Corporation announced the immediate March 31, 2026 departure of its Chief Medical Officer Steven Ryder, M.D. alongside formal separation terms.

Key takeaways

Steven Ryder, M.D. departs as Rallybio CMO immediately effective March 31, 2026.
Dr. Ryder receives standard no-cause severance per his existing employment agreement.
Additional change-of-control severance applies post closing of the Candid Therapeutics merger.

Full analysis

Dr. Ryder had served as Rallybio's Chief Medical Officer since January 2019, marking a change to the company's longstanding clinical leadership. A portion of his severance is tied to the closing of the pending merger with Candid Therapeutics, with payouts structured per his existing employment agreement and the Merger Agreement terms. The complete separation agreement will be filed as part of Rallybio's Q1 2026 Form 10-Q.